---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-072821"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T03:51:08.999404+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cara Therapeutics cuts workforce 70% after discontinuing NP program, explores strategic alternatives

## Summary
- Board approved streamlined operating plan and strategic alternatives after discontinuing NP program following KOURAGE-1 Part A results on June 12, 2024.
- Workforce reduction of approximately 70%, substantially complete by June 30, 2024.
- Expects approximately $2.6M in total charges for termination benefits, recognized in Q2 and Q3 2024.

## SEC filing metadata
- accession: 0001104659-24-072821
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465924072821/0001104659-24-072821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465924072821/tm2417536d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-072821
- JSON: https://secwatch.observer/filing/0001104659-24-072821.json
- Plain text: https://secwatch.observer/filing/0001104659-24-072821.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.